ReviewJACC. Heart failure2016
Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps.
Review in JACC. Heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.Cardiology journal · 2019Trial
- Burden of heart failure in Asian Countries from 1990 to 2021: Update from the Global Burden of Disease Study 2021.PloS one · 2026Article
- The Asia Pacific Cardiovascular Research (ASPIRE) Network: Facilitating and Advancing Regional Cardiovascular Clinical Trials.JACC. Asia · 2025Article
- Current and Future of Heart Failure Care in Asia.International journal of heart failure · 2024Review
- Body mass index, frailty, and outcomes in heart failure with preserved ejection fraction.ESC heart failure · 2024Article
- Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial.JACC. Asia · 2024Article
- Observational
- Lagging behind the Western countries: the knowledge gaps of gender differences in heart failure in Asia.ESC heart failure · 2023Review
- Predicting Heart Failure in Patients with Atrial Fibrillation: A Report from the Prospective COOL-AF Registry.Journal of clinical medicine · 2023Article
- Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects.JACC. Asia · 2022Review
- Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.JACC. Asia · 2022Article
- Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction.JACC. Asia · 2022Article
- Relationship between body roundness index and the risk of heart failure in Chinese adults: the Kailuan cohort study.ESC heart failure · 2022Article
- Hypertensive Heart Failure in Asia.Pulse (Basel, Switzerland) · 2021Review
- Validation of Three European Risk Scores to Predict Long-Term Outcomes for Patients Receiving Cardiac Resynchronization Therapy in an Asian Population.Journal of cardiovascular translational research · 2021Observational
- Clinical Phenotypes and Age-Related Differences in Presentation, Treatment, and Outcome of Heart Failure with Preserved Ejection Fraction: A Vietnamese Multicenter Research.Cardiology research and practice · 2021Article
- Acute decompensated heart failure in a non cardiology tertiary referral centre, Sarawak General Hospital (SGH-HF).BMC cardiovascular disorders · 2020Observational
- Outcomes of Asian-Americans Implanted With Left Ventricular Assist Devices: An Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Analysis.Heart, lung & circulation · 2020Article
- Risk stratification in patients hospitalized for acute heart failure in Asian population.Journal of the Chinese Medical Association : JCMA · 2020Article
- Clinical Approach to Shortening Length of Hospital Stay in Elderly Patients With Acute Heart Failure Requiring Intensive Care.Circulation reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Heart failure (HF) is a major and increasing global public health problem. In Asia, aging populations and recent increases in cardiovascular risk factors have contributed to a particularly high burden of HF, with outcomes that are poorer than those in the rest of the world. Representation of Asians in landmark HF trials has been variable. In addition, HF patients from Asia demonstrate clinical differences from patients in other geographic regions. Thus, the generalizability of some clinical trial results to the Asian population remains uncertain. In this article, we review differences in HF phenotype, HF management, and outcomes in patients from East and Southeast Asia. We describe lessons learned in Asia from recent HF registries and clinical trial databases and outline strategies to improve the potential for success in future trials. This review is based on discussions among scientists, clinical trialists, industry representatives, and regulatory representatives at the CardioVascular Clinical Trialist Asia Forum in Singapore on July 4, 2014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.